

Malawi

Support for Vaccine: Measles Rubella
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Malawi							
2. Vaccine grant number: 1516-MWI-09a-X, 1820-MWI-09a-X							
3. Date of Decision Letter: 10 September 2019							
4. Date of the Partnership Framework Agreement: 29 October 2013							
5. Programme title: New Vaccine Support (NVS), Measles Rubella, SD Routine - Strat 1							
6. Vaccine type: Measles Rubella							
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED							
8. Programme Duration:¹ 2015-2019							
9. Programme Budget (indicative):² (subject to the terms of the Partnership Framework Agreement, if applicable)							
	2015-2018	2019	2020	2021	2022	2023	Total ²
Programme Budget (US\$)	866,339	247,000	-	-	-	-	1,113,339
10. Vaccine introduction grant Not applicable							
11. Product switch grant Not applicable							
12. Indicative Annual Amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)							
Type of supplies to be purchased with Gavi funds	2015-2018		2019				
Number of vaccine doses			792,400				
Annual Amounts (US\$)	866,339		247,000				
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
14. Self-procurement: Not applicable							
15. Co-financing obligations: Not applicable							
16. Operational support for campaigns: Not applicable							

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Not applicable

19. Other conditions:

As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2019
Number of doses of vaccines for Measles Second Dose approved by Gavi.	792,400
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	242,474
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	378,866
Number of doses of Measles-Rubella vaccine to be funded by country.	413,534
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	264,662

Signed by,

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
10 September 2019